Production (Stage)
Outlook Therapeutics, Inc.
OTLK
$1.90
$0.031.60%
NASDAQ
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -22.86% | |||
| Gross Profit | -- | 22.86% | |||
| SG&A Expenses | -33.17% | 15.38% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -42.65% | -5.55% | |||
| Operating Income | 42.65% | 5.55% | |||
| Income Before Tax | -366.75% | 205.34% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -366.76% | 205.34% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -366.76% | 205.34% | |||
| EBIT | 42.65% | 5.55% | |||
| EBITDA | 42.71% | 5.56% | |||
| EPS Basic | -309.39% | 198.92% | |||
| Normalized Basic EPS | -294.54% | 195.04% | |||
| EPS Diluted | -309.39% | 198.92% | |||
| Normalized Diluted EPS | -294.54% | 195.04% | |||
| Average Basic Shares Outstanding | 27.40% | 2.14% | |||
| Average Diluted Shares Outstanding | 27.40% | 2.14% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||